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The birth prevalence rate of each common autosomal trisomy generally
increases with advancing maternal age and there is a substantial fetal loss rate
between late first trimester and term. The literature is reviewed in order to pro-
vide the best estimates of these rates, taking account where possible of biases
due to prenatal diagnosis and selective termination of pregnancy. There is an
almost exponential increase in Down syndrome birth prevalence between ages
15 and 45 but at older ages the curve flattens. There is no evidence of the
claimed relatively high birth prevalence at extremely low ages. Gestation-
specific intra-uterine fetal loss rates are estimated by follow-up of women
declining termination of pregnancy after prenatal diagnosis, comparison of
observed rates with those expected from birth prevalence and comparison of
age-specific curves developed for prenatal diagnosis and birth. Down syndrome
fetal loss rates reduce with gestation and increase with maternal age. Edwards
and Patau syndrome birth prevalence is approximately 1/8 and 1/13 that of
Down syndrome overall, although the ratio differs according to maternal age,
particularly for Patau syndrome where it reduces steadily from 1/9 to 1/19.
Fetal loss rates are higher for Edwards and Patau syndromes than for Down
syndrome.
In this review, we consider the common autosomal trisomies,
defined as an extra copy of chromosome 21, 18 or 13 (Down,
Edwards and Patau syndromes) whose birth prevalence
increases with maternal age. Among the common sex chromo-
some abnormalities birth prevalence is not universally associated
with age: 47, XXY and 47, XXX increase, 47, XYY is unaltered and
monosomy X (Turner syndrome) declines.1 For each type of tri-
somy, maternal age-specific prevalence rates are estimated at
birth and according to gestational age. Claims are examined that
in women aged 45 of more prevalence does not continue to
increase and in those aged 15 or less prevalence is
relatively high.
1 | DOWN SYNDROME: EARLY STUDIES
OF ADULTS AND CHILDREN
The discovery of a maternal age effect was made by Lionel Penrose.
This arose from his study of 1280 residents of the Royal Eastern
Counties Institution in Colchester, England and their families.2 Pen-
rose belief that mental abnormality had a biological rather than social
aetiology was confirmed by the survey. It yielded clear evidence to
support a number of salient features of mental abnormality: an excess
of males, heterogeneity of expression and continuum between normal
and intellectual impairment. This seminal work led to more focussed
investigation including a study of 63 residents with Down syndrome
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where Penrose observed an association with increased maternal and
paternal ages. In a more detailed study with a larger population, he
was able to show, using regression analysis, that the primary effect
was maternal age.3
2 | DOWN SYNDROME: MATERNAL AGE-
SPECIFIC BIRTH PREVALENCE RATES
2.1 | Methodology
The only unequivocal estimates of age-specific prevalence are avail-
able from studies carried out before invasive prenatal diagnosis for
aneuploidy became clinically established. Prenatal diagnosis and
subsequent termination of affected pregnancies will necessarily
reduce birth prevalence and this will not be uniform across all mater-
nal ages. When advanced maternal age was the only indication for
prenatal diagnosis it was still possible to estimate prevalence at
younger ages, say, less than 35. When maternal serum and, later,
ultrasound marker screening became widespread the problem
became exacerbated. Screening combined information on the
marker profile and maternal age calculate a personalised DS risk
which was used to select those at high enough risk to warrant the
costs and hazards of prenatal diagnosis. Consequently, the propor-
tion of affected pregnancies diagnosed and terminated varied
according to maternal age. During this phase, it was possible to esti-
mate birth prevalence from the observed numbers of affected births
and affected terminations but required assumptions to be made
about intra-uterine viability. Where possible, the best estimate of
prevalence is based on the meta-analysis of individual studies, ide-
ally fitting a simple curve to the data.
2.2 | Early studies and four meta-analyses
In the late 1980s, a meta-analysis was carried out using data from all
eight studies published at that time.4 This included with a total of
4528 DS births and more than 5 million unaffected births. The studies
were from Australia (1960-1977), Belgium (1971-1978), Canada
(1961-1970), Sweden (1968-1970), United States (Massachusetts
(1958-1965), New York (1968-1974), Ohio (1970-1979)) and Wales
(1968-1976). Five used multiple sources to identify DS births includ-
ing birth certificates, hospital and mental health institution records,
cytogenetic laboratories, special schools and sheltered workshops.
Two studies, in New York and Ohio, used only birth certificates but
were adjusted for under-ascertainment, increasing the number of
cases 2.66- and 2.74-fold, respectively, based on a comparison of
cytogenetic records and birth certificates. The last study was based
solely on newborn examinations by an obstetrician and paediatrician.
For each year of age, from 15 to 50, data were pooled by taking the
average birth prevalence rate across the studies weighted by the num-
ber of births. A three parameter, additive-exponential regression
equation was used of the form, y = a + exp(b + cx), where y is
prevalence and x is age. A single regression was performed over the
entire age range.
The second meta-analysis used the same eight studies.5 Pooling was
by summation of the birth prevalence numerators and denominators at
ages 15 to 50. Two different additive-exponential regression equations
were fitted: three parameter, and five parameters with a cubic exponential
component. Separate analyses were carried out for the two series that the
authors regarded as most complete—from Belgium and Sweden—and
restricting maternal age range in four ways (15-49, 20-49, 15-45 and
20-45). Unlike the first meta-analysis, four terminations of pregnancy fol-
lowing prenatal diagnosis of Down syndrome at amniocentesis in the
Wales study were reduced by 30% to allow for fetal loss (see Section 3).
The third meta-analysis comprised five studies.6 This included the
two “most complete” studies from the second meta-analysis replaced by
a study in Belgium, which extended the series to 1971-1990 and comple-
mented by a more recent study in Sweden (1971-1977). The study in
Australia was also replaced by a more extended series 1960-1989
although data from 1960 to 1964 were not included because of concerns
about completeness. The fifth “Intensive Newborn” study combined data
from studies in Winnipeg and Edinburgh where all neonates had cytoge-
netic tests. Pooling was by summation at each maternal age, 16 to 49.
Three-, five- and six-parameter additive-exponential regression equations
were used, the latter having a quartic exponential component. A separate
analysis was carried out after excluding the Australia study. A total of
110 terminations of Down syndrome pregnancies diagnosed following
amniocentesis were reduced by 30%.
The fourth meta-analysis included nine studies, all but two of
those in the first meta-analysis (New York and Wales), making the
replacements (Australia and Belgium) and additions (Sweden and
What is already known about this topic
• Birth prevalence of each common autosomal trisomy
increases with maternal age
• Each trisomy has high intra-uterine fatality
• Down syndrome fetal loss rates increase with mater-
nal age
What does this study add
• A review of all published estimates of prevalence at term
and during pregnancy
• Confirms flattening of the Down syndrome birth preva-
lence curve at extremely high maternal ages
• Dismisses the claimed relatively high Down syndrome
birth prevalence at extremely low ages
• Shows that Patau syndrome birth prevalence increases
with maternal age less rapidly than Down syndrome
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Intensive Newborn) from the third meta-analysis, together with a
study of Down syndrome births from a different part of Australia
(1987-1991), in women aged 36 or more.7 Pooling was by the use of
a weighting factor which estimated the proportional under-
ascertainment in each study. The regression analysis simultaneously
estimated the curve parameters and this proportion over the maternal
age range 16 to 50. A three parameter logistic regression equation
was used of the form, y = a + (1 − a)/(1 + exp[−b − cx]), where a is
between 0 and 1. A separate analysis was carried out after excluding
the Canada study. The numbers of terminated pregnancies were
reduced by 30%.
2.3 | National Down Syndrome Cytogenetic
Register (NDSCR)
NDSCR receives reports of cases with a DS karyotype from all clinical
cytogenetic in England and Wales; this is the largest national consecu-
tive series of such cases.8 The register used data on 11 683 DS cases
reported in 1989-1998 to estimate maternal age-specific prevalence
rates, more than double the total number included in a meta-analysis.9
Prevalences were calculated at maternal age 11 to 55 from the num-
ber of births according to age in England and Wales in 1990-1998
obtained from the Office of National Statistics. Unlike the early stud-
ies this series was strongly biased by prenatal diagnosis which
accounted for 5276 cases (45%) of which 82% were known to have
been terminated. In order to allow for this, after all cases were
increased by 6% to allow for under-ascertainment, the number of ter-
minated cases was reduced by 43% if prenatal diagnosis followed cho-
rionic villus sampling (CVS) and by 23% if it followed amniocentesis.
For terminated cases, the maternal age was calculated assuming that
the pregnancy would have delivered at 38 weeks gestation, the modal
value for DS births in the study. A four-parameter logistic regression
curve was fitted to the data including all maternal ages with the form,
y = 1/(1 − exp(a + b/(1 + exp[c + d*age])))). Separate analyses were
carried out for births in 1989-1993 and 1994-1998 but there were no
material differences.
2.4 | Comparison between curves
Over the 15- to 40-year age range, there is little difference between
each of the 19 regression curves from the four meta-analyses or the
NDSCR regression curve (Table 1). At age 45, differences emerge with
estimated prevalence ranging from 27.8/1000 to 43.0/1000; but at
age 50, there is an almost fivefold range of values from 38.5/1000 to
188/1000. The curves that yield the lowest values at older ages are
either additive-exponential with higher order parameters or logistic.
Table 2 shows the observed age-specific prevalence rates for
each single year of age between 45 and 49 or more in 10 studies
included in the four meta-analyses, in NDSCR and 87 cases from
12 of the congenital malformations registries belonging to the
European network EUROCAT.20 For Australia and Belgium, the
studies in the second meta-analysis replacing those in the first meta-
analysis were used, except that the 1960-1964 data from Australia
was not excluded. The study from Wales did not include data in this
maternal age range.
The tabulated maternal age-specific birth prevalence rates are
higher at all ages in the meta-analyses than in the NDSCR and
EUROCAT data, but all series combined indicates a flattening within
this age range. This could be, at least in part, due to bias. One possibil-
ity is that, there the observation is an artefact due to errors in the
recording of maternal age. Pregnancy at such advanced reproductive
ages is relatively uncommon and a proportion of those recorded as
aged over 45 may in fact be younger and have a lower DS prevalence.
One group of pregnancies where age might be under-recorded are
those achieved by assisted-reproductive technology (ART) using
either a donor oocyte or an autologous frozen embryo transfer. The
recorded age should be that of the donor or the woman at the time of
storage rather than the literal maternal age. However, most of the
pregnancies included in Table 2 occured before 1990, when ART was
not very common, and this is unlikely to have contributed to the over-
all result.
There are also possible biological explanations. In older women,
the Down syndrome fetal loss rate following prenatal diagnosis is rela-
tively high (discussed below) but losses are likely to be even higher
before prenatal diagnosis. Specifically, with the approach of meno-
pause the number of available oocytes declines leading to fewer
recognised pregnancies and the number of abnormal oocytes
(resulting in trisomic conceptions) may decline even more than normal
oocytes (resulting in non-trisomic conceptions). Double and triple
aneuploidy with trisomy 21 and another autosomal trisomy or mono-
somy X are more common at advanced ages8 and are excluded from
DS prevalence rates.
Even if bias has substantially contributed to the flattening of the
maternal age-specific curve, it would be reasonable to use a single
birth prevalence estimate for all women aged 45 or more. Since the
95% confidence intervals (CIs) on the age-specific estimates in this
range largely overlap, the number of cases and pregnancies can be
combined. This yields an overall prevalence of 34.1 per 1000
(454/13304) with 95% CI 31.2-37.3. The age-specific and overall esti-
mates are shown together with the 95% CIs in Figure 1.
Table 3 shows the observed age-specific prevalence rates for
each single year of age between 15 or less and 19 in nine studies
included in the four meta-analyses and in the NDSCR. There are no
substantial differences at any age in this range between prevalence in
the meta-analyses and NDSCR, and the rates are consistent with a
baseline low prevalence as assumed with the use of an additive expo-
nential curve.
The results are inconsistent with the suggestion that the preva-
lence of Down syndrome is relatively high at extremely young ages.21
This was found in a USA register of malformations, the National Cleft
Lip and Palate Intelligence Service during 1961-1966, which included
4925 Down syndrome births obtained from birth certificates. A repre-
sentative 1% sample of unaffected controls was obtained from the
same referral areas as the cases and no adjustment was made for
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under-ascertainment. The prevalence in those aged under 15 was,
after allowing for the sample control proportion, 0.682 per 1000
(3/44; 95% CI 0.235-1.82) compared with the rate at age 15-19 of
0.208 per 1000 (239/11502; 95% CI 0.183-0.236). It is noteworthy
though that prevalence was low at all ages in the 15-45 range indicat-
ing considerable under-ascertainment of Down syndrome which
might have not been present in the youngest group.
3 | DOWN SYNDROME: INTRA-UTERINE
VIABILITY
Three approaches have been used to estimate the DS fetal loss rate
between CVS or amniocentesis and term. These are (1) follow-up of
individuals declining an offer of termination of pregnancy after pre-
natal diagnosis, (2) comparison of observed number of cases at the
time of prenatal diagnosis to the number expected from the mater-
nal age-specific prevalence curves at birth and (3) comparison of
age-specific curves developed for the time of prenatal diagnosis
with those at birth. The estimates for approaches (1) and (2) are
shown in Table 4.
3.1 | Declining termination
The combined results from three amniocentesis series including a
total of 110 cases in women having prenatal diagnosis for advanced
age observed a 29% fetal loss rate.22 However, such direct follow-up
is potentially biased since some miscarriages will have occurred in
women who did intend to have a pregnancy termination, thus inflating
the rate. Actuarial survival analysis rather than direct follow-up has
been carried out for NDSCR data.23 Not only does this overcome the
bias, but it is more data efficient since all cases contribute to the esti-
mate, not just those in which pregnancy termination was refused.
During the period 1989-1996, among a total of 2035 cases diagnosed
by amniocentesis carried out at 16-18 weeks gestation the estimated
loss rate was 24%. There were also 441 cases diagnosed by CVS car-
ried out at 11-13 weeks and the fetal loss rate was 31%. During this
TABLE 1 Estimated Down syndrome birth prevalence (/1000) at selected maternal ages from 20 regression curves
Regression curvea
Maternal age (years)
15 20 25 30 35 40 45 50
Meta-analyses
First4
Eight studies, Additive-exponential (3) 0.634 0.654 0.740 1.10 2.60 8.86 35.0 144
Second5
Eight studies, Additive-exponential (3) 0.634 0.654 0.740 1.10 2.62 8.97 35.6 147
Eight studies, 15–45 age range 0.637 0.656 0.740 1.10 2.60 9.01 36.2 152
Eight studies, 15–49 age range 0.632 0.653 0.740 1.10 2.62 8.97 35.6 147
Eight studies, 20–45 age range 0.644 0.663 0.745 1.10 2.60 9.01 36.4 153
Eight studies, 20–49 age range 0.638 0.659 0.744 1.10 2.61 8.96 35.7 148
Two studies, 15–45 age range 0.594 0.616 0.711 1.12 2.87 10.4 42.7 181
Two studies, 15–49 age range 0.590 0.613 0.711 1.12 2.88 10.3 42.0 177
Two studies, 20–45 age range 0.636 0.655 0.740 1.12 2.81 10.4 44.1 195
Two studies, 20–49 age range 0.630 0.650 0.738 1.13 2.83 10.3 43.0 186
Eight studies, Additive-exponential (5) 0.648 0.661 0.740 1.08 2.59 9.26 34.3 99.4
Third6
Five studies, Additive-exponential (3) 0.642 0.666 0.764 1.17 2.87 9.96 39.4 162
Five studies, Additive-exponential (5) 0.664 0.678 0.766 1.14 2.86 10.4 37.0 96.9
Five studies, Additive-exponential (6) 0.588 0.659 0.782 1.16 2.78 10.5 36.9 54.8
Four studies, Additive-exponential (3) 0.661 0.682 0.777 1.18 2.92 10.4 42.5 180
Four studies, Additive-exponential (5) 0.659 0.679 0.781 1.18 2.89 10.5 41.8 145
Four studies, Additive-exponential (6) 0.510 0.655 0.798 1.19 2.81 10.7 41.9 102
Fourth7
Eight studies, Logistic (4) 0.688 0.710 0.803 1.20 2.90 10.1 39.6 184
Seven studies, Logistic (4) 0.667 0.692 0.794 1.22 2.97 10.2 38.9 142
NDSCR9,10
Logistic (4) 0.660 0.677 0.746 1.06 2.83 11.6 27.8 38.5
aThe number of parameters is shown in parenthesis.
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period, of the DS cases diagnosed prenatally in England and Wales
the indication for invasive testing was advanced age in 40%, serum
screening in 34% and ultrasound screening in 20%, the remainder
because of family history and third trimester ultrasound.30 The state-
wide California screening programme reported the direct follow-up of
392 pregnancies detected by screening and declining termination; the
fetal loss rate was only 10%.24 However, the authors suggested that
the low rate may be due to some miscarriages having been classified
as terminations of pregnancy. The screening programme relies on
reporting by obstetrical practioners and it is possible that some
women who originally chose to continue the pregnancy changed their
mind without informing the provider.
3.2 | Prenatal diagnoses and number expected
from birth prevalence
A number of studies have used this approach in women having
prenatal diagnosis because of advanced age. In one study three
series, two of them previously published, were combined yielding
estimated loss rates after CVS and amniocentesis of 54% and
33%, respectively.25 In another study from the same group, two
different previously published series were combined with an esti-
mated rate after amniocentesis of 31%.26 The group later consid-
erably extended one of the original series and reanalysed the data
to allow for the increase in maternal age between prenatal diag-
nosis and term.27 This yielded much lower loss rates after CVS,
32% and after amniocentesis, 22%. Another study included five
series, three of which were included in the above analyses, and
found loss rates of 54% and 32% after CVS and amniocentesis.28
One of the studies of DS births according to maternal age over
36 in Australia which was included in one of the meta-analyses
also included data on prenatal diagnoses.19 A statistical model
was fitted and the estimated fetal loss rates were much lower
than the other studies—31% and 18% after CVS and amniocente-
sis, but the numbers of cases were small and the upper 90% confi-
dence limits were 52% and 38%, respectively. Finally, modelling
was also used on the combined data in older women from series
TABLE 2 Observed Down syndrome birth prevalence in single years of maternal ages from age 45 to 49, and older, in 12 studies
Studies
Maternal age (years)
45 46 47 48 ≥49
Meta-analyses
New York 1968-197411a 40/1111 27/514 8/183 3/65 5/38
Massachusetts 1958-196512 20/638 9/258 7/103 2/41 0/38
Canada 1971-197813 11/327 — — — —
Sweden 1968-197014 9/161 7/82 1/35 2/19 0/9
Ohio 1970-197915a 16/405 16/188 3/77 0/18 5/20
Sweden 1971-197716 9/217 5/105 0/41 — —
Belgium 1971-199017 4/112 3/74 1/3 1/6 0/3
Australia (Southern) 1960-198918 9/301 3/170 1/56 1/24 0/12
Intensive newborn 1967-19736 2/19 1/7 1/2 — —
Australia (Victoria) 1987-199119c 0/20 0/23 1/14 0/5 0/4
Total 120/3311 71/1421 23/514 9/178 10/124











NDSCR9b 69/2277 33/1073 20/535 5/293 7/646
EUROCAT20 45/1620 21/686 15/303 4/125 2/198
Total 114/3897 54/1759 35/838 9/418 9/844











Total 234/7208 125/3180 58/1352 18/596 19/968










Abbreviation: CI, confidence interval, based on Wilson score.
aNumerators adjusted for under-reporting on birth certificates.
bNumerators adjusted for under-reporting and terminations of pregnancy.
cExcluding prenatal diagnoses.
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included some of the studies of births (five), amniocentesis (three)
and CVS (six).29 Again the estimated loss rates were low at 39%
and 12%.
3.3 | Potential confounding and bias
A problem with these analyses is that the maternal age, serum and
ultrasound screening indications for invasive testing are associated
with altered a prior risk of fetal loss generally and could potentially
disproportionately influence fetal losses rates in DS pregnancies
which are already vulnerable.
A large population-based epidemiological study from Denmark
has demonstrated that among pregnancies in general, the probability
of miscarriage increases steadily with age from 9% at 20-24 to 75% at
45 or older.31 Since, karyotype analysis is not routinely carried out on
material obtained after miscarriage it is not known if aneuploidy per
se contributes to the increasing rates.
Fetal demise is associated with abnormal screening marker levels:
in the first trimester, low pregnancy-associated plasma protein
(PAPP)-A, low or high free β-human chorionic gonadotrophin (hCG),
very large nuchal translucency (NT) or cystic hygroma; in the second
trimester, low α-fetoprotein or unconjugated estriol, high hCG or
inhibin-A.32 The marker profile in women who are referred for inva-
sive testing because of a screen-positive result varies according to
maternal age. For example, in young women with a screen-positive
combined tests PAPP-A will be lower, free β-hCG and NT higher than
older women with screen-positive results who might have moderate
marker profiles and a higher risk just because of relatively
advanced age.
3.4 | Maternal and gestational age-specific rates
Comparison of maternal age-specific prevalence according to ges-
tational age with that at birth has been carried out in two studies.
The first study included three series in women aged 36 or more
and was discussed above in relation to the overall fetal loss rate.27
Relative prevalence compared to births was analysed and over this
range it was not significantly related to maternal age but reduced
with gestation: 1.57 at 9-10, 1.35 at 11-14 and 1.29 at
15-16 weeks, equivalent to fetal loss rates of 34%, 26% and 22%,
respectively. The second study was from NDSCR including 5177
prenatally diagnosed cases, more than 10 times larger than the
first study and represented the entire maternal age range of
15-50.33 A subset of the cases had been included in a previous
study of fetal loss which like this also used an actuarial survival
analysis.23 Proportional hazards regression was used to assess any
effect on survival of maternal age, stratified by CVS or amniocen-
tesis and gestational age. This showed a statistically significant
increase in losses with maternal age from the time of CVS and
from amniocentesis: at age 25, 23% and 19%; at 35, 32% and 25%;
and at 45, 44% and 33%.
When the first study27 was combined with three further series of
older women,19,26,28 it was confirmed that the fetal loss rate from the
time of CVS increased with maternal age but there was no statistically
significant comparable increase from the time of amniocentesis.33 It
remains possible that the discrepancy between these studies and
NDSCR is due to confounding with screening markers in younger
women.
A consequence of an association between DS fetal loss and
maternal age is that the estimated maternal age-specific birth
prevalence rates in some studies will have been distorted. In stud-
ies which included a large numbers of terminated DS pregnancies
and the number was reduced by applying a single overall fetal loss
rate will have under-estimated prevalence at younger ages and
over-estimated it at older ages. It is also possible that the associa-
tion has contributed to the observed flattening of the birth preva-
lence curve at advanced maternal ages. However, this is unlikely
to explain all the effect since the rate of increase in fetal losses
with age is much less than the expected exponential increase in
births.
4 | IMPLICATIONS FOR DOWN
SYNDROME SCREENING
4.1 | Age-specific prior risk
Screening programmes differ in time referred to by the computed risk:
term, mid-second trimester, late first trimester or the gestational week
of screening. Those computing term risks—the probability of having a
DS birth in the absence of detection and termination of pregnancy—
use one of the published age-specific birth prevalence curves. How-
ever, since the curves were constructed from prevalence at completed
F IGURE 1 Observed Down syndrome birth prevalence and 95%
confidence interval at maternal age 45 or more from 12 studies
combined6,9,11-20:
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years of age, they need to be modified to accurately estimate risk at
the estimated date of delivery in years and decimals by subtracting
0.5 years assuming that the prevalence relates to the middle of the
year. For the mid-second and late-first trimester referral points either
an overall fetal loss factor from DS loss rates after amniocentesis or
CVS is applied to the term prior risk or a maternal age-specific factor
is used.
4.2 | Monitoring performance
The expected detection and false-positive rates for different multi-
marker screening policies can be derived from statistical modelling
based on the assumption of multi-variate log Gaussian methods distri-
butions of the multi-marker profile. An observed maternal age distri-
bution can be used, usually a national population whose maternal age
TABLE 3 Observed Down syndrome birth prevalence in single years of maternal ages from age 15 or younger to 19, in 10 studies
Studies
Maternal age years
≤15 16 17 18 19
Meta-analyses
New York 1968-197411a 3/5142 11/12524 19/27701 37/51057 43/80075
Massachusetts 1958-196512 1/1364 2/3959 10/9848 9/19632 24/32687
Canada 1971-197813 — — — 15/13675 16/18752
Sweden 1968-197014 0/383 1/1979 3/5265 10/9212 4/13433
Ohio 1970-197915a 5/11114 14/24404 30/45190 33/65802 63/84721
Sweden 1971-197716 — 0/3321 3/8883 8/15891 23/25262
Belgium 1971-199017 0/797 0/2681 4/5834 5/10664 9/18405
Australia (Southern) 1960-198918 1/1611 4/4212 4/9517 6/15711 13/21829
Intensive newborn 1967-19736 0/55 0/228 0/457 0/799 1/1013
Total 10/20464 32/53308 73/159695 123/202443 196/296177











NDSCR9b 6/13068 18/36962 51/82120 70/125464 116/166520











Total 16/33532 50/90270 124/241815 193/327907 312/462697










Abbreviation: CI, confidence interval, based on Wilson score.
aNumerators adjusted for under-reporting on birth certificates.
bNumerators adjusted for under-reporting and terminations of pregnancy.
TABLE 4 Estimated Down syndrome
fetal loss rate (95% CI) from CVS and
amniocentesis to birth, in 9 studies
Studies Indication CVS Amniocentesis
Declining termination
22 Maternal age — 29% (21-38%)
23 Mixed 31% (13-64%) 24% (17-34%)
24 Screening — 10% (8.6-14%)
Prenatal diagnoses and expected births
25 Maternal age 54% (48-61%) 33% (30-36%)
26 Maternal age — 27% (25-30%)
27 Maternal age 32% (26-38%) 22% (18-27%)
28 Maternal age 54% (48-60%) 32% (26-39%)
19 Maternal age 31% (22-43%) 18% (11-29%)
29 Maternal age 39% (34-43%) 12% (10-14%)
Abbreviation: CI, confidence interval, calculated by the authors or based on Wilson score.
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structure has been published, or a Gaussian distribution of maternal
ages.34
Deriving the performance of a specific policy in practise is not so
straightforward. The observed false-positive rate is reliable, but the
observed detection rate will necessarily be inflated due to viability
bias. One unbiased estimate is derived from the observed numbers of
Down syndrome cases: screen detected terminated (n1) or not (n2),
missed by screening but terminated subsequently (n3) or born (n4);
using the formula (n1*p + n2)/(n1*p + n2 + n3*p + n4), where p is the
intra-uterine survival rate for Down syndrome at the time of prenatal
diagnosis. Another approach is to calculate e which is the expected
number of DS births, given the maternal age distribution of screened
women and use the formula 1 − (n2 + n4)/e.
5 | EDWARDS AND PATAU SYNDROMES
5.1 | Birth prevalence
Three studies, one of which combined multiple series, have reported
aneuploidy rates following routine karyotyping of consecutive neonates
in the era before widespread prenatal diagnosis.35-37 The total numbers
of Down, Edwards and Patau syndrome births were 143, 20 and
7, respectively. Hence, the birth prevalence of Edwards syndrome was
1/7 that of Down syndrome and Patau syndrome was 1/20.
5.2 | Maternal age-specific rates
These rates can be derived from a large study of these trisomies in nine
regional multi-source congenital abnormality register, seven members of
the British Isles Network of Congenital Anomaly Registers (BINOCAR)
and two in Australia.38 There were a total of 2254 with Edwards syn-
drome and 975 with Patau syndrome of which 59% and 57%, respec-
tively, ended in termination of pregnancy. To allow for fetal losses, rates
were applied according to trisomy, gestation and gender, which had been
derived in another BINOCAR study discussed below.39 Logistic regression
was carried out on the observed age-specific prevalences. Based on the
regression curves the overall prevalence was for Edwards syndrome 1/8
of that for Down syndrome based on the NDSCR regression curve10 and
for Patau syndrome the overall prevalence was 1/13 of Down syndrome.
For both Edwards and Patau syndrome, the curves showed a flattening
after age 45. Table 5 shows the regressed prevalences for selected mater-
nal ages between 20 and 45, and Figure 2 shows the regression curves.
Edwards syndrome prevalence relative to Down syndrome varied with
age; Patau syndrome prevalence relative to Down syndrome reduced
steadily with age, halving between 20 and 45.
5.3 | Intra-uterine viability
The frequency of autosomal trisomies in spontaneous abortions indi-
cates that viability is considerably lower for Edwards and Patau syn-
dromes compared with Down syndrome. In a meta-analysis, the total
numbers of Down, Edwards and Patau syndrome miscarriages were
121, 46 and 35, respectively, prevalence ratios of 1/3 and 1/4 which
are two- to fourfold higher than at birth.40
Table 6 shows the estimated Edwards and Patau syndromes fetal
loss rates in women declining termination of pregnancy and based on
comparison of observed cases with those expected from maternal
age-specific birth prevalence.
Two large studies have reported fetal loss rates in women who
decline termination of pregnancy following amniocentesis. One study,
including three series, reported fetal loss rates for Edwards and Patau
syndromes of 68% (27/40) and 40% (4/10), respectively.22 A study
from the state-wide California screening programme followed-up
106 Edwards syndrome and reported only 34 fetal deaths (32%).24
The same study found a relatively low fetal loss rate for DS pregnan-
cies, possibly due to misclassification of some miscarriages as termina-
tions of pregnancy (see above). Combining data from five small
studies in women refusing termination after prenatal diagnosis the
loss rate for Edwards syndrome was 70% (30/43) and for Patau syn-
drome 37% (20/54).41-45
Only one study estimated Edwards and Patau syndrome fetal loss
rates by comparing the number of prenatal diagnoses, in older women,
with that expected from birth prevalence rates.26 The estimated loss
rates for Edwards syndrome from the time of CVS and amniocentesis
were 87% and 77%; for Patau syndrome 82% and 69%, respectively.
However, the expected number was calculated indirectly from the
overall relative prevalence compared with Down syndrome based on
routine karyotyping of consecutive neonates.35 Hence, in addition to
being based on small numbers of Edwards and Patau syndrome
TABLE 5 Estimated Down, Edwards
and Patau syndrome birth prevalence at
selected maternal ages (/1000 and
relative to Down syndrome)a
Disorder
Maternal age (years)
20 25 30 35 40 45
Down syndrome (DS) 0.677 0.746 1.06 2.83 11.6 27.8
Edwards syndrome (ES) 0.112 0.116 0.139 0.283 1.36 4.68
Patau syndrome (PS) 0.0733 0.0764 0.0932 0.195 0.698 1.46
ES/DS 1/6 1/6 1/8 1/10 1/9 1/6
PS/DS 1/9 1/10 1/11 1/14 1/17 1/19
aFrom logistic regression curves: Down syndrome tabulated values10; Edwards and Patau syndromes
directly from the curves.38
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neonates, it makes the assumption that relative incidence is unrelated
to maternal age.
More reliable loss rates are provided by a study from five
members of BINOCAR, which included 475 Edwards and
175 Patau syndrome cases diagnosed prenatally and followed-
up.39 Actuarial survival analysis estimated that for Edwards syn-
drome the loss rates from 12 and 18 weeks were 72% and 65%;
for Patau syndrome 49% and 42%, respectively. A similar study,
but much larger study from NDSCR provides gestational age-
specific fetal loss rates for each syndrome.46 The actuarial survival
rates from 12 and 18 weeks were for 4088 Edwards syndrome
cases, 70% and 65%; for 1471 Patau syndrome cases 50% and
43%, respectively.
Early small studies reported that the Edwards syndrome fetal loss
rate was higher in males than females.22 This was confirmed by the
large BINOCAR study with loss rates from 12 weeks of 79% and 67%,
and from amniocentesis, 85% and 64%, respectively,39 and by the
NDSCR study.46 However, none of these gender effects was statisti-
cally significant.
6 | ORIGINS OF ANEUPLOIDY
The rapid increase in prevalence of the common autosomal trisomies
over much of the maternal age range has generated a number of
aetiological hypotheses. Production line—oocytes formed in late fetal
life are more susceptible to mal-segregation and the order in which
they eventually ovulate mirrors that in which they were produced.47
Ageing oocyte—disturbances during stages of oogenesis, particularly
meiotic arrest, are responsible.48 Relaxed selection—the propensity for
selection against trisomy, whereby affected fetuses are miscarried,
decreases in older mothers.49 Premature reproductive ageing—
physiological ageing, for example depletion of the oocyte pool by
accelerated atresia, is more important than chronological age per se.50
Other aneuploidies of meiotic origin are also associated with
advancing maternal age. However, the shapes of the curve may differ;
for some such as trisomy 16 this is because of a greater propensity
for mal-segregation,51 while some are more susceptible to early fetal
loss due to greater imbalance.52 In contrast, mitotic errors are largely
not associated with age.53 This might explain why the Patau syndrome
prevalence relative to Down syndrome reduced steadily with age
since a larger proportion of the former are mosaic.
The proportion of common autosomal trisomies births attribut-
able to maternal age depends on the age distribution. It has been esti-
mated that for England and Wales, in 2017, the proportion was about
three-quarters.54 The identification of causal factors in the remaining
cases is difficult to establish because of strong confounding by age
and gestation.
The reason why some affected pregnancies with common autoso-
mal trisomies are non-viable while others survive to term is not known
unknown and a search for differentiating genetic or other factors
would be valuable. It has been suggested that in Edwards and Patau
syndromes, the presence of a diploid cell line in the placenta enhances
intra-uterine survival, although this is not a pre-requisite.55
F IGURE 2 Estimated Down, Edwards and Patau syndrome birth
prevalences, according to maternal ages from logistic regression
curves in References 10 and 38
TABLE 6 Estimated Edwards and
Patau syndrome fetal loss rates (95% CI),
in 10 studies
Studies Diagnosis Edwards syndrome Patau syndrome
Declining termination
22 Amniocentesis 68% (52-80%) 40% (17-69%)
24 Amniocentesis 32% (24-42%) —
41-45 Prenatal diagnosis 70% (55-81%) 37% (25-50%)
Prenatal diagnoses and expected births
25 CVS 87% (76-93%) 82% (64-93%)
Amniocentesis 77% (71-82%) 69% (56-78%)
39 12 weeks 72% (61-81%) 49% (29-73%)
18 weeks 65% (59-79%) 42% (18-72%)
46 12 weeks 70% (66-75%) 50% (42-59%)
18 weeks 65% (60-70%) 43% (35-53%)
Abbreviation: CI, confidence interval, calculated by the authors or based on Wilson score.
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7 | CONCLUSIONS
Several curves have been developed to describe the increase in Down
syndrome birth prevalence with advancing maternal age, based on
meta-analysis or by the extensive data from a single national register.
The curves do not differ substantially over the range 16-44 with a
slow increase only doubling by about age 30, and doubling again by
35 with a much steeper increase thereafter. At age 45 or older rates
flatten and a single prevalence rate is applicable. There is no evidence
that prevalence at age 15 or lower is higher than age 16-19. Edwards
syndrome birth prevalence increases at a similar rate to Down syn-
drome, albeit not uniformly, but for Patau syndrome the increase is
shallower. All three common autosomal trisomies have high intrauter-
ine fatality. The fetal loss rate in Down syndrome increases with
maternal age and is higher for Edwards syndrome with Patau syn-
drome having an intermediate rate.
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